Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sam Ahn

Allergy & Immunology Napa, CA Medical Doctor

NPI 1558423814 CMS profile 251791

1100 Pear Tree Ln, Napa, CA 94558

Open in the dashboard

General payments

$24,785

498 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$80,068 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Sam Ahn of Napa, CA is reported in the CMS Open Payments database as having received $24,785 across 498 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $80,068 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,313 105
2024 General $3,424 78
2023 General $2,807 97
2022 General $8,496 78
2021 General $3,106 77
2020 General $1,478 26
2019 General $1,162 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sam Ahn
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Sam Ahn were reported at $4,313. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Sam Ahn Allergy & Immunology median Middle half National median
2019 $1,162 $378 $115–$1,178 $163
2020 $1,478 $303 $75–$1,581 $114
2021 $3,106 $407 $122–$1,475 $132
2022 $8,496 $357 $120–$1,340 $149
2023 $2,807 $445 $124–$1,536 $160
2024 $3,424 $541 $129–$1,763 $164
2025 $4,313 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bio Products Laboratory USA, Inc. $6,963 17 payments
  2. Genentech USA, Inc. $3,759 38 payments
  3. Genzyme Corporation $3,185 62 payments
  4. AstraZeneca Pharmaceuticals LP $1,796 53 payments
  5. OptiNose US, Inc. $1,205 20 payments
  6. GlaxoSmithKline, LLC. $1,179 56 payments
  7. Regeneron Healthcare Solutions, Inc. $792 25 payments
  8. CSL Behring $690 35 payments
  9. Grifols USA, LLC $590 18 payments
  10. Amgen Inc. $540 18 payments
  11. Other $4,086 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,695 478 payments
  2. Honoraria $5,000 1 payment
  3. Consulting Fee $4,861 8 payments
  4. Travel and Lodging $1,122 3 payments
  5. Education $107 8 payments
Products named General payments · program years 2019–2025
  1. Xolair $3,811 39 payments
  2. DUPIXENT Immunology $2,672 81 payments
  3. Xhance $1,205 20 payments
  4. TEZSPIRE Respiratory $876 20 payments
  5. TRELEGY ELLIPTA $733 27 payments
  6. DUPIXENT Inflammation And Immunology $695 21 payments
  7. Xembify $547 16 payments
  8. TEZSPIRE Inflammation $485 16 payments
  9. NUCALA $406 27 payments
  10. Hizentra $350 21 payments
  11. Other $5,628 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,918

Median for Allergy/ Immunology: 449

Drug cost

$1,106,813

Median for Allergy/ Immunology: $169,700

Branded share of claims

50.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 73 $306,236
Xolair Omalizumab Brand 70 $195,687
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 24 $176,103
Tezspire Tezepelumab-Ekko Brand 37 $142,367
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 120 $92,258
Spiriva Respimat Tiotropium Bromide Brand 33 $32,721
Breo Ellipta Fluticasone/Vilanterol Brand 42 $20,512
Ipratropium Bromide Generic 256 $13,751
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 23 $13,029
Alvesco Ciclesonide Brand 17 $11,470

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$717,627

Of which drugs: $560,774

Medicare patients

544

Average age 73

Services billed

37,771

369 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 47%
Osteoporosis 24%
Diabetes 19%
Ischemic heart disease 17%
Cancer 16%
Depression 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 23 13,695 $408,697
Vaccine for influenza for injection into muscle 90662 Office 58 58 $4,746

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $699
  • Regeneron Healthcare Solutions, Inc. $88
$787 73 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $250
  • Amgen Inc. $157
$408 37 —
XOLAIR
  • Genentech USA, Inc. $187
  • Novartis Pharmaceuticals Corporation $80
$267 70 13,695
FASENRA
  • AstraZeneca Pharmaceuticals LP $100
$100 — —
Xembify
  • Grifols USA, LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record